This data supports work looking at scalable manufacturing of liposomes without using any solvents. This dataset contains data of particle size, PDI, zeta potential, drug release and drug loading of several formulations investigated in this paper.
Abstract: Objectives. A major challenge faced with the manufacture of liposomes is the high volumes of solvents used and disposed of during manufacturing. Therefore, we have developed a solvent-free production of drug-loaded liposomes and demonstrated it applicability with both aqueous core loaded and bilayer loaded drugs.
Methods. Liposomes were produced by high-shear mixing lipids in a dried powder state, followed by down-sizing of the liposomes using a Microfluidizer® processor. Liposomes were purified via tangential flow filtration and characterised in terms of size, polydispersity and drug loading.
Key findings. Doxorubicin-loaded PEGylated liposomes can be manufactured using this solvent-free method with particle sizes of 100-110 nm, low PDI (<0.2) and high drug loading (97-98 %). If required, the liposomes can be further down-sized via further microfluidic processing without impacting on drug loading. Similar results were achieved with non-pegylated liposomes. With bilayer loaded amphotericin B liposomes, again liposomes could be prepared in a clinically appropriate size range (100 – 110 nm in size, low PDI) with high drug loading (98 - 100 %).
Conclusions. We have demonstrated a simple and scalable solvent-free method for the production of liposomes that can be employed for both aqueous core loaded and bilayer loaded liposomes.